$AVAH

Raymond James Names Top Healthcare Stocks for August

Raymond James updated its August healthcare top picks, adding Aveanna Healthcare (AVAH) ahead of its Aug. 13 earnings, and Carriage Services (CSV) after a ~20% decline since April, citing stabilizing funeral trends and valuation around 8x 2027 estimated EBITDA. It also added Viking Therapeutics (VKTX) for upcoming clinical readouts.

Original reporting
Published Aug 6, 2026, 1:46 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefSector analysis
Primary signal
$AVAH
Bullish
medium confidence
Mentioned
$AVAH · $CSV · $VKTX
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$AVAHBullishLow
01

Why it matters

This is primarily a catalyst calendar and sentiment update. It may influence short-term positioning, but it does not introduce new financial guidance or newly released clinical outcomes in the text.

02

Market read

Traders may use the article as a timing reference for upcoming earnings/readouts, but it is not a primary disclosure of new results.

03

What to watch

Key risk is that the article provides expectations (upcoming catalysts) rather than results; traders should wait for the actual earnings/clinical readouts to confirm the thesis.

Relevance 4/10Novelty 3/10Timing: into upcoming earnings/readout windows referenced by the analyst list (Aug. 13 for AVAH; later this year for VKTX)

Background

Raymond James updated its monthly healthcare top picks, replacing one name on the list and adding two others based on upcoming earnings dates and expected clinical catalysts.

Company-level read

Ticker impact

$AVAHBullishMedium confidence
Context

Raymond James added Aveanna Healthcare to its healthcare top picks ahead of its Aug. 13 earnings report, citing near-term upside catalysts.

Expected impact

Likely modest, short-term sentiment support into the Aug. 13 earnings window; follow-through depends on the actual print.

Evidence & confidence

The article provides a specific timing catalyst (Aug. 13 earnings) and a stated thesis (rate increase discussion), but no new company financials or guidance.

$CSVBullishMedium confidence
Context

Raymond James added Carriage Services to top picks, pointing to stabilizing funeral trends and a valuation discount versus Service Corp.

Expected impact

Potential for incremental buying interest, but magnitude likely limited without a new earnings/guidance datapoint in the text.

Evidence & confidence

The article cites CDC-consistent trends and a peer multiple comparison, plus a stated ~20% decline since April, but does not disclose new company-specific results or guidance.

$VKTXBullishMedium confidence
Context

Raymond James added Viking Therapeutics to top picks, citing upcoming catalysts including initial readouts for VK2735 and VK3019.

Expected impact

Moderate upside bias into the expected readout windows later this year; price reaction will hinge on actual data.

Evidence & confidence

The text names specific pipeline programs and expected readout types, but it is framed as outlook rather than newly reported clinical outcomes.

Market effects

Reinforces a near-term bullish bias in healthcare names with identifiable catalysts (earnings or clinical readouts), but does not change sector fundamentals.

No specific regional policy or macro shock tied to the named stocks.

Limited, as the catalysts are company-specific and the piece is an analyst monthly list update.

Counterpoint

Analyst “top picks” updates can be largely promotional and may not translate into sustained performance without new earnings, guidance, or trial data.

Key entities

  • Raymond James

    Updated its monthly healthcare sector top picks with three named companies and stated catalyst rationales.

  • Aveanna Healthcare

    Added to the top picks ahead of Aug. 13 earnings, with a thesis tied to near-term sentiment drivers.

  • Carriage Services

    Added to the top picks based on stabilizing funeral trends and a valuation discount versus a peer.

  • Viking Therapeutics

    Added to the top picks based on expected near-term clinical readouts for VK2735 and VK3019.

Related articles

$VKTXMedAI 8/10

Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?

Viking Therapeutics (VKTX) reported a wider Q2 2026 net loss of $128.02 million and filed a universal shelf registration plus a $500 million at-the-market common stock offering, expanding funding options. The article links these moves to investor expectations for VK2735 obesity drug development, noting dilution and cash burn risks and citing forecasts of $118.5 million revenue and $12.9 million earnings by 2029.

$VKTXMed

Viking Therapeutics, Inc. (VKTX): Results of Operations and Financial Condition

Viking Therapeutics, Inc. (VKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enroll

$AVAHMed

Bain, KKR, KV Asia shortlisted for Malaysia’s Avisena Healthcare stake sale as valuation hits US$368 million: sources

Bain Capital, KKR and KV Asia have been shortlisted to buy a 20–25% minority stake in Malaysia’s Avisena Healthcare, valuing the company at about RM1.5 billion (US$368m), according to two sources. Binding bids are due by end-July. The stake is estimated at RM300–400m. KKR and Bain declined comment; Avisena and KV Asia did not respond.

$VKTXMedAI 8/10

Truist Financial Begins Coverage on Viking Therapeutics (NASDAQ:VKTX)

Truist Financial began coverage of Viking Therapeutics (VKTX) with a “buy” rating and an $83.00 price target, implying 159.5% upside from the prior close, according to the firm. Other analysts set targets from $95 to $102 and ratings ranging from “buy” to “sell.” VKTX shares traded at $31.99 midweek; it reported Q1 EPS of ($1.37), missing the ($1.01) consensus.